267 related articles for article (PubMed ID: 19836479)
1. A novel form of 4-1BBL has better immunomodulatory activity than an agonistic anti-4-1BB Ab without Ab-associated severe toxicity.
Schabowsky RH; Elpek KG; Madireddi S; Sharma RK; Yolcu ES; Bandura-Morgan L; Miller R; MacLeod KJ; Mittler RS; Shirwan H
Vaccine; 2009 Dec; 28(2):512-22. PubMed ID: 19836479
[TBL] [Abstract][Full Text] [Related]
2. A Novel Form of 4-1BBL Prevents Cancer Development via Nonspecific Activation of CD4
Barsoumian HB; Batra L; Shrestha P; Bowen WS; Zhao H; Egilmez NK; Gomez-Gutierrez JG; Yolcu ES; Shirwan H
Cancer Res; 2019 Feb; 79(4):783-794. PubMed ID: 30770367
[TBL] [Abstract][Full Text] [Related]
3. Adjuvantive effects of anti-4-1BB agonist Ab and 4-1BBL DNA for a HIV-1 Gag DNA vaccine: different effects on cellular and humoral immunity.
Ganguly S; Liu J; Pillai VB; Mittler RS; Amara RR
Vaccine; 2010 Feb; 28(5):1300-9. PubMed ID: 19944789
[TBL] [Abstract][Full Text] [Related]
4. A switch in costimulation from CD28 to 4-1BB during primary versus secondary CD8 T cell response to influenza in vivo.
Bertram EM; Dawicki W; Sedgmen B; Bramson JL; Lynch DH; Watts TH
J Immunol; 2004 Jan; 172(2):981-8. PubMed ID: 14707071
[TBL] [Abstract][Full Text] [Related]
5. Constitutive interaction between 4-1BB and 4-1BBL on murine LPS-activated bone marrow dendritic cells masks detection of 4-1BBL by TKS-1 but not 19H3 antibody.
Mbanwi AN; Lin GHY; Wang KC; Watts TH
J Immunol Methods; 2017 Nov; 450():81-89. PubMed ID: 28789924
[TBL] [Abstract][Full Text] [Related]
6. 4-1BB ligand-mediated costimulation of human T cells induces CD4 and CD8 T cell expansion, cytokine production, and the development of cytolytic effector function.
Wen T; Bukczynski J; Watts TH
J Immunol; 2002 May; 168(10):4897-906. PubMed ID: 11994439
[TBL] [Abstract][Full Text] [Related]
7. Engineered soluble, trimerized 4-1BBL variants as potent immunomodulatory agents.
Battin C; De Sousa Linhares A; Leitner J; Grossmann A; Lupinek D; Izadi S; Castilho A; Waidhofer-Söllner P; Grabmeier-Pfistershammer K; Stritzker J; Steinberger P
Cancer Immunol Immunother; 2023 Sep; 72(9):3029-3043. PubMed ID: 37310433
[TBL] [Abstract][Full Text] [Related]
8. Dispensable role for 4-1BB and 4-1BBL in development of vaccinia virus-specific CD8 T cells.
Zhao Y; Croft M
Immunol Lett; 2012 Jan; 141(2):220-6. PubMed ID: 22037570
[TBL] [Abstract][Full Text] [Related]
9. CD28-independent, TRAF2-dependent costimulation of resting T cells by 4-1BB ligand.
Saoulli K; Lee SY; Cannons JL; Yeh WC; Santana A; Goldstein MD; Bangia N; DeBenedette MA; Mak TW; Choi Y; Watts TH
J Exp Med; 1998 Jun; 187(11):1849-62. PubMed ID: 9607925
[TBL] [Abstract][Full Text] [Related]
10. 4-1BB ligand as an effective multifunctional immunomodulator and antigen delivery vehicle for the development of therapeutic cancer vaccines.
Sharma RK; Schabowsky RH; Srivastava AK; Elpek KG; Madireddi S; Zhao H; Zhong Z; Miller RW; Macleod KJ; Yolcu ES; Shirwan H
Cancer Res; 2010 May; 70(10):3945-54. PubMed ID: 20406989
[TBL] [Abstract][Full Text] [Related]
11. 4-1BB ligand induces cell division, sustains survival, and enhances effector function of CD4 and CD8 T cells with similar efficacy.
Cannons JL; Lau P; Ghumman B; DeBenedette MA; Yagita H; Okumura K; Watts TH
J Immunol; 2001 Aug; 167(3):1313-24. PubMed ID: 11466348
[TBL] [Abstract][Full Text] [Related]
12. Costimulation as a platform for the development of vaccines: a peptide-based vaccine containing a novel form of 4-1BB ligand eradicates established tumors.
Sharma RK; Elpek KG; Yolcu ES; Schabowsky RH; Zhao H; Bandura-Morgan L; Shirwan H
Cancer Res; 2009 May; 69(10):4319-26. PubMed ID: 19435920
[TBL] [Abstract][Full Text] [Related]
13. Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with FcγR affinity.
Qi X; Li F; Wu Y; Cheng C; Han P; Wang J; Yang X
Nat Commun; 2019 May; 10(1):2141. PubMed ID: 31105267
[TBL] [Abstract][Full Text] [Related]
14. The systemic administration of Ig-4-1BB ligand in combination with IL-12 gene transfer eradicates hepatic colon carcinoma.
Xu DP; Sauter BV; Huang TG; Meseck M; Woo SL; Chen SH
Gene Ther; 2005 Oct; 12(20):1526-33. PubMed ID: 15973445
[TBL] [Abstract][Full Text] [Related]
15. Ex vivo expansion of CD4+CD25+FoxP3+ T regulatory cells based on synergy between IL-2 and 4-1BB signaling.
Elpek KG; Yolcu ES; Franke DD; Lacelle C; Schabowsky RH; Shirwan H
J Immunol; 2007 Dec; 179(11):7295-304. PubMed ID: 18025172
[TBL] [Abstract][Full Text] [Related]
16. A novel agonist of 4-1BB costimulatory receptor shows therapeutic efficacy against a tobacco carcinogen-induced lung cancer.
Gulen AE; Rudraboina R; Tarique M; Ulker V; Shirwan H; Yolcu ES
Cancer Immunol Immunother; 2023 Nov; 72(11):3567-3579. PubMed ID: 37605009
[TBL] [Abstract][Full Text] [Related]
17. SA-4-1BBL costimulation inhibits conversion of conventional CD4+ T cells into CD4+ FoxP3+ T regulatory cells by production of IFN-γ.
Madireddi S; Schabowsky RH; Srivastava AK; Sharma RK; Yolcu ES; Shirwan H
PLoS One; 2012; 7(8):e42459. PubMed ID: 22870329
[TBL] [Abstract][Full Text] [Related]
18. In vivo triggering through 4-1BB enables Th-independent priming of CTL in the presence of an intact CD28 costimulatory pathway.
Diehl L; van Mierlo GJ; den Boer AT; van der Voort E; Fransen M; van Bostelen L; Krimpenfort P; Melief CJ; Mittler R; Toes RE; Offringa R
J Immunol; 2002 Apr; 168(8):3755-62. PubMed ID: 11937526
[TBL] [Abstract][Full Text] [Related]
19. Expression of 4-1BB and 4-1BBL in thymocytes during thymus regeneration.
Kim YM; Kim HK; Kim HJ; Lee HW; Ju SA; Choi BK; Kwon BS; Kim BS; Kim JB; Lim YT; Yoon S
Exp Mol Med; 2009 Dec; 41(12):896-911. PubMed ID: 19745604
[TBL] [Abstract][Full Text] [Related]
20. 4-1BB ligand activates bystander dendritic cells to enhance immunization in trans.
Macdonald DC; Hotblack A; Akbar S; Britton G; Collins MK; Rosenberg WC
J Immunol; 2014 Nov; 193(10):5056-64. PubMed ID: 25305314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
